View Full Paper

Cover Page

Scoping Review on Pharmacological Agents for Preventing Decompensation in Compensated Liver Cirrhosis Excluding Beta-Blockers

Student Name

Course Name

Instructor Name

Institution

Date

Study Selection and Evidence Identification Process

PRISMA Flow Diagram

Study Selection Results

Characteristics of Included Pharmacological Studies

Overview of Included Studies

Therapeutic Classes Evaluated

Study Designs and Patient Populations

Clinical Outcomes Across Included Studies

Comparative Clinical Outcomes of Pharmacological Interventions

Statins

Rifaximin

Anticoagulants

SGLT-2 Inhibitors

GLP-1 Receptor Agonists

Other Emerging Therapies

Risk of Bias and Quality Assessment of Included Evidence

Assessment Methods

Summary of Risk of Bias Findings

Evaluation of Current Evidence and Research Limitations

Strengths of the Evidence Base

Weaknesses of Existing Studies

Major Research Gaps

Evaluation of Promising Pharmacological Strategies for Preventing Cirrhosis Decompensation

Statins as Vascular Protective Agents

Rifaximin and Gut–Liver Axis Modulation

Anticoagulants for Portal Vein Thrombosis Prevention

Clinical Implications and Future Research Priorities

Implications for Clinical Practice

Recommendations for Future Research

Integrated Conclusions and Future Directions

Overall Findings

Evidence-Based Recommendations

References